Skip to content

Effect of Valerian on Anxiety and Quality of Life in Patients with Type 1 Diabetes

The Effect of Oral Capsule Valerian on Anxiety and Quality of life in Patients With Type 1 Diabetes

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20181126041754N1
Enrollment
92
Registered
2018-12-18
Start date
2018-06-08
Completion date
Unknown
Last updated
2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety. Generalized anxiety disorder

Interventions

Intervention 1: Intervention group: The intervention in the intervention group included the daily intake of one oral capsule valerian 530 mg, 60 minutes before bedtime for eight weeks.In order to ensu

Sponsors

Sanandaj University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 18 Years

Inclusion criteria

Inclusion criteria: Patients with type 1 diabetes Age of 14-18 years Ensure full vigilance Have reading and writing skills Ability to communicate Satisfaction to participate in the study Have a lasting diagnosis of diabetes for at least a year Not having a history of liver and kidney disease Not having a history of mental illness

Exclusion criteria

Exclusion criteria: Use of any hypnotic and analgesic drug drug allergy Pregnancy and lactation Taking heparin by the patient Unwilling to participate in the study being admitted to the hospital

Design outcomes

Primary

MeasureTime frame
Anxiety Score in Beck's Inventory. Timepoint: Befor the intervention, four weeks after the intervention, eight weeks after the intervention. Method of measurement: Beck Anxiety Inventory.

Secondary

MeasureTime frame
Quality of Life Score. Timepoint: Before the intervention, eight weeks after the intervention. Method of measurement: Thomas and Associates Quality of Life Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public Contact????? ?????

Sanandaj University of Medical Sciences

s.salehi1863@gmail.com+98 87 3233 5445

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026